San Luis Coyotzingo (MX)
{name}
{subtitle}
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
city
~27 mi. (Ciudad de Atlixco, Mexico, +271 more cities)
facility
Local Institution
condition
Prostate Adenocarcinoma
drug
docetaxel, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
city
~27 mi. (Ciudad de Atlixco, Mexico, +172 more cities)
facility
Local Institution
condition
Urothelial Carcinoma
drug
cisplatin, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.
city
~27 mi. (Ciudad de Atlixco, Mexico, +137 more cities)
facility
Local Institution
condition
Bladder Urothelial Carcinoma
drug
bempegaldesleukin, +2 more drugs
drug type
immunotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~27 mi. (Ciudad de Atlixco, Mexico, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
condition
Breast Carcinoma
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
city
~27 mi. (Ciudad de Atlixco, Mexico, +126 more cities)
facility
Centro Oncologico Medica Sur
condition
Non-Small Cell Lung Carcinoma
drug
nivolumab, +2 more drugs
drug type
chemotherapy, +1 more type
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
city
~27 mi. (Ciudad de Atlixco, Mexico, +60 more cities)
facility
Local Institution
condition
Hepatocellular Carcinoma
drug
nivolumab, +1 more drug
drug type
immunotherapy
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~64 mi. (Mexico City, Mexico, +192 more cities)
facility
Grupo Medico Camino Sc
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~64 mi. (Mexico City, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types